LEADER 02075nam 2200409 450 001 9910633973003321 005 20230325123059.0 010 $a1-83962-793-X 035 $a(CKB)5700000000338630 035 $a(NjHacI)995700000000338630 035 $a(EXLCZ)995700000000338630 100 $a20230325d2022 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aKetamine Revisited $eNew Insights into NMDA Inhibitors /$fedited by Nieves Saiz-Sapena, Manuel Granell Gil 210 1$aLondon :$cIntechOpen,$d2022. 210 4$dİ2022 215 $a1 online resource (300 pages) 311 $a1-83962-792-1 320 $aIncludes bibliographical references and index. 327 $a1. Introduction -- 2. Ketamine and its molecular effects -- 2.1 Immediate effects -- 2.2 Disruption of NMDA channel functions by ketamine -- 2.3 Ketamine possesses delayed effects -- 3. Psychotomimetic effects of ketamine -- 4. Hypnosis -- 5. Pain -- 5.1 Control of chronic pain -- 6. Antidepressant effects of ketamine -- 7. Conclusion -- Funding -- Declaration of interest -- References. 330 $aIn the past, ketamine was considered a dangerous medication with the potential for abuse as a recreational drug. Healthcare providers were warned of its dangers and taught to fear its use. With this book, we hope to eliminate any fear and misgivings associated with this drug. It can be a useful medication in many situations, some of which we describe herein. This book discusses the use of ketamine in anesthesia, pain disorders, depression, palliative care, and trauma situations. It also examines ketamine usage in developing countries. 517 $aKetamine Revisited 606 $aKetamine 615 0$aKetamine. 676 $a615.781 702 $aGil$b Manuel Granell 702 $aSaiz-Sapena$b Nieves 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910633973003321 996 $aKetamine Revisited$93086574 997 $aUNINA